Other pharmacovigilance studies have demonstrated disproportionate reporting for bullous pemphigoid (BP) associated with DPP-4 inhibitors (gliptins), supporting the hypothesis of a potential class effect. Here, DPP4 is linked to bullous pemphigoid.